Intra-arterial Interleukin-2 for Head and Neck Cancer
Author Information
Author(s): M.E. Gore, P. Riches, K. MacLennan, M. O'Brien, J. Moore, G. Dadian, A. Lorentzos, R. Garth, E. Moskovic, D. Archer, N. Breach, M. Henk, P. Rhys-Evans, D.M. King
Primary Institution: Royal Marsden Hospital, London; Charing Cross/Westminster Medical School, London, UK.
Hypothesis
Can intra-arterial administration of interleukin-2 improve treatment outcomes for patients with squamous cell carcinoma of the head and neck?
Conclusion
Intra-arterial IL-2 at lower doses does not cause significant systemic side effects, but higher doses lead to toxicity similar to intravenous administration.
Supporting Evidence
- Patients treated at lower dose levels did not experience significant systemic side effects.
- At the highest dose level, patients experienced systemic toxicity similar to intravenous IL-2.
- Local complications included tumor pain and facial edema, which were not dose-related.
Takeaway
Doctors gave a special medicine called IL-2 directly to the tumors in people's necks to see if it would help them get better, and they found that it worked better at lower doses without making them very sick.
Methodology
This was a phase I dose escalation study where IL-2 was administered via intra-arterial infusion to patients with incurable squamous cell carcinoma.
Potential Biases
Potential bias due to the small number of participants and the specific selection criteria for patient eligibility.
Limitations
The study had a small sample size and was limited to patients with specific eligibility criteria.
Participant Demographics
12 patients (9 male, 3 female) with a median age of 55 years (range 31-72).
Want to read the original?
Access the complete publication on the publisher's website